NCT07217184 - Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

April 17, 2025

Study Completion Date

March 11, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Isatuximab

Isatuximab will be administered.

Trial Locations (19)

3065

GSK Investigational Site, Fitzroy

11528

GSK Investigational Site, Athens

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

30322

GSK Investigational Site, Atlanta

44033

GSK Investigational Site, Ulsan

49546

GSK Investigational Site, Grand Rapids

53792

GSK Investigational Site, Madison

94805

GSK Investigational Site, Villejuif

02215

GSK Investigational Site, Boston

41253-190

GSK Investigational Site, Salvador

04537-080

GSK Investigational Site, São Paulo

M5G 2M9

GSK Investigational Site, Toronto

01330

GSK Investigational Site, Mexico City

0450

GSK Investigational Site, Oslo

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

SE-791 82

GSK Investigational Site, Falun